JAYPIRCA (Eli Lilly Australia Pty Ltd)
Product name
JAYPIRCA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
164 (255 working days)
Active ingredients
pirtobrutinib
Registration type
NCE/NBE
Indication
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JAYPIRCA as monotherapy is indicated for the treatment of adult patients with relapsed orrefractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have been previously treated with a covalent Bruton's tyrosine kinase (BTK) inhibitor.